Natural killer and natural killer T cells in liver fibrosis

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1832, Issue 7, 2013, Pages 1061-1069

  Gao, Bin ^a   Radaeva, Svetlana ^a  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

Alcoholic liver disease; IFN gamma; NAFLD; NKG2D; Viral hepatitis

Indexed keywords

ALPHA INTERFERON; GAMMA INTERFERON; INTERLEUKIN 13; INTERLEUKIN 4; OSTEOPONTIN; SONIC HEDGEHOG PROTEIN;

CELL POPULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; FIBROGENESIS; HUMAN; HUMAN CELL; LIVER FIBROSIS; NATURAL KILLER CELL; NATURAL KILLER T CELL; PRIORITY JOURNAL; REVIEW; SENESCENCE; ANIMAL; HEPATIC STELLATE CELL; LIVER CIRRHOSIS;

ANIMALIA; ERINACEIDAE; HEPATITIS C VIRUS;

ANIMALS; HEPATIC STELLATE CELLS; HUMANS; KILLER CELLS, NATURAL; LIVER CIRRHOSIS; NATURAL KILLER T-CELLS;

EID: 84877076614     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2012.09.008     Document Type: Review

References (93)

1. Friedman S.L. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008, 134:1655-1669.
2. Bataller R., Brenner D.A. Liver fibrosis. J. Clin. Invest. 2005, 115:209-218.
3. Friedman S.L. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol. Rev. 2008, 88:125-172.
4. Pinzani M., Macias-Barragan J. Update on the pathophysiology of liver fibrosis. Expert Rev. Gastroenterol. Hepatol. 2010, 4:459-472.
5. Marra F., Aleffi S., Galastri S., Provenzano A. Mononuclear cells in liver fibrosis. Semin. Immunopathol. 2009, 31:345-358.
6. Duffield J.S., Forbes S.J., Constandinou C.M., Clay S., Partolina M., Vuthoori S., Wu S., Lang R., Iredale J.P. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J. Clin. Invest. 2005, 115:56-65.
7. Connolly M.K., Bedrosian A.S., Mallen-St Clair J., Mitchell A.P., Ibrahim J., Stroud A., Pachter H.L., Bar-Sagi D., Frey A.B., Miller G. In liver fibrosis, dendritic cells govern hepatic inflammation in mice via TNF-alpha. J. Clin. Invest. 2009, 119:3213-3225.
8. Jiao J., Sastre D., Fiel M.I., Lee U.E., Ghiassi-Nejad Z., Ginhoux F., Vivier E., Friedman S.L., Merad M., Aloman C. Dendritic cell regulation of carbon tetrachloride-induced murine liver fibrosis regression. Hepatology 2012, 55:244-255.
9. Gao B., Radaeva S., Park O. Liver natural killer and natural killer T cells: immunobiology and emerging roles in liver diseases. J. Leukoc. Biol. 2009, 86:513-528.
10. Lanier L.L. NK cell recognition. Annu. Rev. Immunol. 2005, 23:225-274.
11. Raulet D.H. Roles of the NKG2D immunoreceptor and its ligands. Nat. Rev. Immunol. 2003, 3:781-790.
12. Ortaldo J.R., Young H.A. Mouse Ly49 NK receptors: balancing activation and inhibition. Mol. Immunol. 2005, 42:445-450.
13. Biron C.A., Nguyen K.B., Pien G.C., Cousens L.P., Salazar-Mather T.P. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu. Rev. Immunol. 1999, 17:189-220.
14. Robertson M.J. Role of chemokines in the biology of natural killer cells. J. Leukoc. Biol. 2002, 71:173-183.
15. Kronenberg M. Toward an understanding of NKT cell biology: progress and paradoxes. Annu. Rev. Immunol. 2005, 23:877-900.
16. Vanderkerken K., Bouwens L., De Neve W., Van den Berg K., Baekeland M., Delens N., Wisse E. Origin and differentiation of hepatic natural killer cells. Hepatology 1993, 18:919-925.
17. Luo D., Vanderkerken K., Bouwens L., Kuppen P.J., Baekeland M., Seynaeve C., Wisse E. The role of adhesion molecules in the recruitment of hepatic natural killer cells (pit cells) in rat liver. Hepatology 1996, 24:1475-1480.
18. Lotzova E. Definition and functions of natural killer cells. Nat. Immun. 1993, 12:169-176.
19. Ishiyama K., Ohdan H., Ohira M., Mitsuta H., Arihiro K., Asahara T. Difference in cytotoxicity against hepatocellular carcinoma between liver and periphery natural killer cells in humans. Hepatology 2006, 43:362-372.
20. Vermijlen D., Luo D., Froelich C.J., Medema J.P., Kummer J.A., Willems E., Braet F., Wisse E. Hepatic natural killer cells exclusively kill splenic/blood natural killer-resistant tumor cells by the perforin/granzyme pathway. J. Leukoc. Biol. 2002, 72:668-676.
21. Radaeva S., Sun R., Jaruga B., Nguyen V.T., Tian Z., Gao B. Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners. Gastroenterology 2006, 130:435-452.
22. Melhem A., Muhanna N., Bishara A., Alvarez C.E., Ilan Y., Bishara T., Horani A., Nassar M., Friedman S.L., Safadi R. Anti-fibrotic activity of NK cells in experimental liver injury through killing of activated HSC. J. Hepatol. 2006, 45:60-71.
23. Jeong W.I., Park O., Radaeva S., Gao B. STAT1 inhibits liver fibrosis in mice by inhibiting stellate cell proliferation and stimulating NK cell cytotoxicity. Hepatology 2006, 44:1441-1451.
24. Radaeva S., Wang L., Radaev S., Jeong W.I., Park O., Gao B. Retinoic acid signaling sensitizes hepatic stellate cells to NK cell killing via upregulation of NK cell activating ligand RAE1. Am. J. Physiol. Gastrointest. Liver Physiol. 2007, 293:G809-G816.
25. Krizhanovsky V., Yon M., Dickins R.A., Hearn S., Simon J., Miething C., Yee H., Zender L., Lowe S.W. Senescence of activated stellate cells limits liver fibrosis. Cell 2008, 134:657-667.
26. Jeong W.I., Park O., Gao B. Abrogation of the antifibrotic effects of natural killer cells/interferon-gamma contributes to alcohol acceleration of liver fibrosis. Gastroenterology 2008, 134:248-258.
27. Hintermann E., Bayer M., Pfeilschifter J.M., Luster A.D., Christen U. CXCL10 promotes liver fibrosis by prevention of NK cell mediated hepatic stellate cell inactivation. J. Autoimmun. 2010, 35:424-435.
28. Muhanna N., Abu Tair L., Doron S., Amer J., Azzeh M., Mahamid M., Friedman S., Safadi R. Amelioration of hepatic fibrosis by NK cell activation. Gut 2011, 60:90-98.
29. Jeong W.I., Park O., Suh Y.G., Byun J.S., Park S.Y., Choi E., Kim J.K., Ko H., Wang H., Miller A.M., Gao B. Suppression of innate immunity (natural killer cell/interferon-gamma) in the advanced stages of liver fibrosis in mice. Hepatology 2011, 53:1342-1351.
30. Hou X., Yu F., Man S., Huang D., Zhang Y., Liu M., Ren C., Shen J. Negative regulation of Schistosoma japonicum egg-induced liver fibrosis by natural killer cells. PLoS Negl. Trop. Dis. 2012, 6:e1456.
31. Gur C., Doron S., Kfir-Erenfeld S., Horwitz E., Abu-Tair L., Safadi R., Mandelboim O. NKp46-mediated killing of human and mouse hepatic stellate cells attenuates liver fibrosis. Gut 2012, 61:885-893.
32. A. Sagiv, M. Yon, J. Simon, S.W. Lowe, V. Krizhanovsky, Granule exocytosis mediates immune surveillance of senescent cells, Oncogene (in press), http://dx.doi.org/10.1038/onc.2012.206.
33. Yoshida K., Ohishi W., Nakashima E., Fujiwara S., Akahoshi M., Kasagi F., Chayama K., Hakoda M., Kyoizumi S., Nakachi K., Hayashi T., Kusunoki Y. Lymphocyte subset characterization associated with persistent hepatitis C virus infection and subsequent progression of liver fibrosis. Hum. Immunol. 2011, 72:821-826.
34. Glassner A., Eisenhardt M., Kramer B., Korner C., Coenen M., Sauerbruch T., Spengler U., Nattermann J. NK cells from HCV-infected patients effectively induce apoptosis of activated primary human hepatic stellate cells in a TRAIL-, FasL- and NKG2D-dependent manner. Lab. Invest. 2012, 92:967-977.
35. K.C. Krämer, B. Kebschull, M. Glässner, A. Eisenhardt, M. Nischalke, H.D. Alexander, M. Sauerbruch, T. Spengler, U. Nattermann J., NKp46(High) expression defines a NK cell subset that is potentially involved in control of HCV replication and modulation of liver fibrosis, Hepatology (in press), http://dx.doi.org/10.1002/hep.25804.
36. Eisenhardt M., Glassner A., Kramer B., Korner C., Sibbing B., Kokordelis P., Nischalke H.D., Sauerbruch T., Spengler U., Nattermann J. The CXCR3(+)CD56Bright phenotype characterizes a distinct NK cell subset with anti-fibrotic potential that shows Dys-regulated activity in hepatitis C. PLoS One 2012, 7:e38846.
37. Taimr P., Higuchi H., Kocova E., Rippe R.A., Friedman S., Gores G.J. Activated stellate cells express the TRAIL receptor-2/death receptor-5 and undergo TRAIL-mediated apoptosis. Hepatology 2003, 37:87-95.
38. Walzer T., Blery M., Chaix J., Fuseri N., Chasson L., Robbins S.H., Jaeger S., Andre P., Gauthier L., Daniel L., Chemin K., Morel Y., Dalod M., Imbert J., Pierres M., Moretta A., Romagne F., Vivier E. Identification, activation, and selective in vivo ablation of mouse NK cells via NKp46. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:3384-3389.
39. Schnabl B., Purbeck C.A., Choi Y.H., Hagedorn C.H., Brenner D. Replicative senescence of activated human hepatic stellate cells is accompanied by a pronounced inflammatory but less fibrogenic phenotype. Hepatology 2003, 37:653-664.
40. Rockey D.C., Maher J.J., Jarnagin W.R., Gabbiani G., Friedman S.L. Inhibition of rat hepatic lipocyte activation in culture by interferon-gamma. Hepatology 1992, 16:776-784.
41. Wolk K., Sabat R. Interleukin-22: A novel T- and NK-cell derived cytokine that regulates the biology of tissue cells. Cytokine Growth Factor Rev. 2006, 17:367-380.
42. F.D. Kong X, Wang H, Hong F, Bertola A, Wang FS, Gao B., Interleukin-22 induces hepatic stellate cell senescence and restricts liver fibrosis, Hepatology 56 (2012) 1150-1159.
43. Meng F., Wang K., Aoyama T., Grivennikov S., Paik Y., Scholten D., Cong M., Iwaisako K., Liu X., Zhang M., Österreicher C., Stickel F., Ley K., Brenner D., Kisseleva T. IL-17 signaling in inflammatory cells, Kupffer cells and hepatic stellate cells exacerbates liver fibrosis. Gastroenterology 2012, 142:765-776.
44. Santodomingo-Garzon T., Swain M.G. Role of NKT cells in autoimmune liver disease. Autoimmun. Rev. 2011, 10:793-800.
45. Notas G., Kisseleva T., Brenner D. NK and NKT cells in liver injury and fibrosis. Clin. Immunol. 2009, 130:16-26.
46. Harada M., Seino K.I., Wakao H., Sakata S., Ishizuka Y., Ito T., Kojo S., Nakayama T., Taniguchi M. Down-regulation of the invariant Valpha14 antigen receptor in NKT cells upon activation. Int. Immunol. 2004, 16:241-247.
47. Eberl G., MacDonald H.R. Rapid death and regeneration of NKT cells in anti-CD3epsilon- or IL-12-treated mice: a major role for bone marrow in NKT cell homeostasis. Immunity 1998, 9:345-353.
48. Venkataswamy M.M., Porcelli S.A. Lipid and glycolipid antigens of CD1d-restricted natural killer T cells. Semin. Immunol. 2010, 22:68-78.
49. Jung K., Park C., Choi Y.H., Jeon Y., Park S.H., Seo S.K., Jin D., Choi I. The protective role of VSIG4 expressed on kupffer cells during immune-mediated liver injury by inducing tolerance of liver T- and NKT-cells. Hepatology 2012, 10.1002/hep.25906.
50. Biburger M., Tiegs G. Alpha-galactosylceramide-induced liver injury in mice is mediated by TNF-alpha but independent of Kupffer cells. J. Immunol. 2005, 175:1540-1550.
51. Parekh V.V., Wilson M.T., Olivares-Villagomez D., Singh A.K., Wu L., Wang C.R., Joyce S., Van Kaer L. Glycolipid antigen induces long-term natural killer T cell anergy in mice. J. Clin. Invest. 2005, 115:2572-2583.
52. de Lalla C., Galli G., Aldrighetti L., Romeo R., Mariani M., Monno A., Nuti S., Colombo M., Callea F., Porcelli S.A., Panina-Bordignon P., Abrignani S., Casorati G., Dellabona P. Production of profibrotic cytokines by invariant NKT cells characterizes cirrhosis progression in chronic viral hepatitis. J. Immunol. 2004, 173:1417-1425.
53. Park O., Jeong W.I., Wang L., Wang H., Lian Z.X., Gershwin M.E., Gao B. Diverse roles of invariant natural killer T cells in liver injury and fibrosis induced by carbon tetrachloride. Hepatology 2009, 49:1683-1694.
54. Ishikawa S., Ikejima K., Yamagata H., Aoyama T., Kon K., Arai K., Takeda K., Watanabe S. CD1d-restricted natural killer T cells contribute to hepatic inflammation and fibrogenesis in mice. J. Hepatol. 2011, 54:1195-1204.
55. Ji Y., Sun S., Xu A., Bhargava P., Yang L., Lam K.S., Gao B., Lee C.H., Kersten S., Qi L. Activation of natural killer T cells promotes M2 macrophage polarization in adipose tissue and improves systemic glucose tolerance via interleukin-4 (IL-4)/STAT6 protein signaling axis in obesity. J. Biol. Chem. 2012, 287:13561-13571.
56. Mantell B.S., Stefanovic-Racic M., Yang X., Dedousis N., Sipula I.J., O'Doherty R.M. Mice lacking NKT cells but with a complete complement of CD8+ T-cells are not protected against the metabolic abnormalities of diet-induced obesity. PLoS One 2011, 6:e19831.
57. Satoh M., Andoh Y., Clingan C.S., Ogura H., Fujii S., Eshima K., Nakayama T., Taniguchi M., Hirata N., Ishimori N., Tsutsui H., Onoe K., Iwabuchi K. Type II NKT cells stimulate diet-induced obesity by mediating adipose tissue inflammation, steatohepatitis and insulin resistance. PLoS One 2012, 7:e30568.
58. Tajiri K., Shimizu Y. Role of NKT cells in the pathogenesis of NAFLD. Int. J. Hepatol. 2012, 2012:850836.
59. Kotas M.E., Lee H.Y., Gillum M.P., Annicelli C., Guigni B.A., Shulman G.I., Medzhitov R. Impact of CD1d deficiency on metabolism. PLoS One 2011, 6:e25478.
60. Li Z., Soloski M.J., Diehl A.M. Dietary factors alter hepatic innate immune system in mice with nonalcoholic fatty liver disease. Hepatology 2005, 42:880-885.
61. Li Z., Oben J.A., Yang S., Lin H., Stafford E.A., Soloski M.J., Thomas S.A., Diehl A.M. Norepinephrine regulates hepatic innate immune system in leptin-deficient mice with nonalcoholic steatohepatitis. Hepatology 2004, 40:434-441.
62. Kremer M., Thomas E., Milton R.J., Perry A.W., van Rooijen N., Wheeler M.D., Zacks S., Fried M., Rippe R.A., Hines I.N. Kupffer cell and interleukin-12-dependent loss of natural killer T cells in hepatosteatosis. Hepatology 2010, 51:130-141.
63. Syn W.K., Oo Y.H., Pereira T.A., Karaca G.F., Jung Y., Omenetti A., Witek R.P., Choi S.S., Guy C.D., Fearing C.M., Teaberry V., Pereira F.E., Adams D.H., Diehl A.M. Accumulation of natural killer T cells in progressive nonalcoholic fatty liver disease. Hepatology 2010, 51:1998-2007.
64. Tajiri K., Shimizu Y., Tsuneyama K., Sugiyama T. Role of liver-infiltrating CD3+CD56+ natural killer T cells in the pathogenesis of nonalcoholic fatty liver disease. Eur. J. Gastroenterol. Hepatol. 2009, 21:673-680.
65. Adler M., Taylor S., Okebugwu K., Yee H., Fielding C., Fielding G., Poles M. Intrahepatic natural killer T cell populations are increased in human hepatic steatosis. World J. Gastroenterol. 2011, 17:1725-1731.
66. Miyagi T., Takehara T., Uemura A., Nishio K., Shimizu S., Kodama T., Hikita H., Li W., Sasakawa A., Tatsumi T., Ohkawa K., Kanto T., Hiramatsu N., Hayashi N. Absence of invariant natural killer T cells deteriorates liver inflammation and fibrosis in mice fed high-fat diet. J. Gastroenterol. 2010, 45:1247-1254.
67. Syn W., Agboola K., Swiderska M., Michelotti G., Liaskou E., Pang H., Xie G., Philips G., Chan I., Karaca G., Pereira Tde A., Chen Y., Mi Z., Kuo P., Choi S., Guy C., Abdelmalek M., Diehl A. NKT-associated hedgehog and osteopontin drive fibrogenesis in non-alcoholic fatty liver disease. Gut 2012, 61:1323-1329.
68. Jin Z., Sun R., Wei H., Gao X., Chen Y., Tian Z. Accelerated liver fibrosis in hepatitis B virus transgenic mice: involvement of natural killer T cells. Hepatology 2011, 53:219-229.
69. Amadei B., Urbani S., Cazaly A., Fisicaro P., Zerbini A., Ahmed P., Missale G., Ferrari C., Khakoo S.I. Activation of natural killer cells during acute infection with hepatitis C virus. Gastroenterology 2010, 138:1536-1545.
70. Ahlenstiel G., Titerence R.H., Koh C., Edlich B., Feld J.J., Rotman Y., Ghany M.G., Hoofnagle J.H., Liang T.J., Heller T., Rehermann B. Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner. Gastroenterology 2010, 138:325-335. (e321-322).
71. Oliviero B., Varchetta S., Paudice E., Michelone G., Zaramella M., Mavilio D., De Filippi F., Bruno S., Mondelli M.U. Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections. Gastroenterology 2009, 137:1151-1160.
72. Golden-Mason L., Bambha K.M., Cheng L., Rosen H.R. Race- and gender-related variation in NKp46 expression associated with differential anti-HCV immunity. Hepatology 2012, 10.1002/hep.25771.
73. Golden-Mason L., Cox A.L., Randall J.A., Cheng L., Rosen H.R. Increased natural killer cell cytotoxicity and NKp30 expression protects against hepatitis C virus infection in high-risk individuals and inhibits replication in vitro. Hepatology 2010, 52:1581-1589.
74. Edlich B., Ahlenstiel G., Azpiroz A.Z., Stoltzfus J., Noureddin M., Serti E., Feld J.J., Liang T.J., Rotman Y., Rehermann B. Early changes in interferon signaling define natural killer cell response and refractoriness to interferon-based therapy of hepatitis C patients. Hepatology 2012, 55:39-48.
75. Stegmann K.A., Bjorkstrom N.K., Veber H., Ciesek S., Riese P., Wiegand J., Hadem J., Suneetha P.V., Jaroszewicz J., Wang C., Schlaphoff V., Fytili P., Cornberg M., Manns M.P., Geffers R., Pietschmann T., Guzman C.A., Ljunggren H.G., Wedemeyer H. Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection. Gastroenterology 2010, 138:1885-1897.
76. Ahlenstiel G., Edlich B., Hogdal L.J., Rotman Y., Noureddin M., Feld J.J., Holz L.E., Titerence R.H., Liang T.J., Rehermann B. Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C. Gastroenterology 2011, 141:1231-1239. (1239 e1231-1232).
77. Stegmann K.A., Bjorkstrom N.K., Ciesek S., Lunemann S., Jaroszewicz J., Wiegand J., Malinski P., Dustin L.B., Rice C.M., Manns M.P., Pietschmann T., Cornberg M., Ljunggren H.G., Wedemeyer H. Interferon alpha-stimulated natural killer cells from patients with acute hepatitis C virus (HCV) infection recognize HCV-infected and uninfected hepatoma cells via DNAX accessory molecule-1. J. Infect. Dis. 2012, 205:1351-1362.
78. Varchetta S., Mantovani S., Oliviero B., Cremonesi E., Ludovisi S., Michelone G., Alessiani M., Rosati R., Montorsi M., Mondelli M.U. Impaired intrahepatic natural killer cell cytotoxic function in chronic hepatitis C virus infection. Hepatology 2012, 56:841-849.
79. Pelletier S., Drouin C., Bedard N., Khakoo S.I., Bruneau J., Shoukry N.H. Increased degranulation of natural killer cells during acute HCV correlates with the magnitude of virus-specific T cell responses. J. Hepatol. 2010, 53:805-816.
80. Wang S.H., Huang C.X., Ye L., Wang X., Song L., Wang Y.J., Liang H., Huang X.Y., Ho W.Z. Natural killer cells suppress full cycle HCV infection of human hepatocytes. J. Viral Hepat. 2008, 15:855-864.
81. Gao B., Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology 2011, 141:1572-1585.
82. Gao B. Alcohol and hepatitis virus interactions in liver pathology. Comprehensive Handbook of Alcohol related Pathology 2005, 2:819-832.
83. Szabo G., Wands J.R., Eken A., Osna N.A., Weinman S.A., Machida K., Joe Wang H. Alcohol and hepatitis C virus-interactions in immune dysfunctions and liver damage. Alcohol. Clin. Exp. Res. 2010, 34:1675-1686.
84. Kenna T., Mason L.G., Porcelli S.A., Koezuka Y., Hegarty J.E., O'Farrelly C., Doherty D.G. NKT cells from normal and tumor-bearing human livers are phenotypically and functionally distinct from murine NKT cells. J. Immunol. 2003, 171:1775-1779.
85. Motohashi S., Ishikawa A., Ishikawa E., Otsuji M., Iizasa T., Hanaoka H., Shimizu N., Horiguchi S., Okamoto Y., Fujii S., Taniguchi M., Fujisawa T., Nakayama T. A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer. Clin. Cancer Res. 2006, 12:6079-6086.
86. Veldt B.J., van der Vliet H.J., von Blomberg B.M., van Vlierberghe H., Gerken G., Nishi N., Hayashi K., Scheper R.J., de Knegt R.J., van den Eertwegh A.J., Janssen H.L., van Nieuwkerk C.M. Randomized placebo controlled phase I/II trial of alpha-galactosylceramide for the treatment of chronic hepatitis C. J. Hepatol. 2007, 47:356-365.
87. Woltman A.M., Ter Borg M.J., Binda R.S., Sprengers D., von Blomberg B.M., Scheper R.J., Hayashi K., Nishi N., Boonstra A., van der Molen R., Janssen H.L. Alpha-galactosylceramide in chronic hepatitis B infection: results from a randomized placebo-controlled Phase I/II trial. Antivir. Ther. 2009, 14:809-818.
88. Gao B., Radaeva S., Jeong W.I. Activation of natural killer cells inhibits liver fibrosis: a novel strategy to treat liver fibrosis. Expert Rev. Gastroenterol. Hepatol. 2007, 1:173-180.
89. Shiratori Y., Imazeki F., Moriyama M., Yano M., Arakawa Y., Yokosuka O., Kuroki T., Nishiguchi S., Sata M., Yamada G., Fujiyama S., Yoshida H., Omata M. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann. Intern. Med. 2000, 132:517-524.
90. Guerret S., Desmouliere A., Chossegros P., Costa A.M., Badid C., Trepo C., Grimaud J.A., Chevallier M. Long-term administration of interferon-alpha in non-responder patients with chronic hepatitis C: follow-up of liver fibrosis over 5 years. J. Viral Hepat. 1999, 6:125-133.
91. Di Bisceglie A.M., Shiffman M.L., Everson G.T., Lindsay K.L., Everhart J.E., Wright E.C., Lee W.M., Lok A.S., Bonkovsky H.L., Morgan T.R., Ghany M.G., Morishima C., Snow K.K., Dienstag J.L. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N. Engl. J. Med. 2008, 359:2429-2441.
92. Cohen-Naftaly M., Friedman S.L. Current status of novel antifibrotic therapies in patients with chronic liver disease. Therap. Adv. Gastroenterol. 2011, 4:391-417.
93. Ono S., Ueno C., Seki S., Matsumoto A., Mochizuki H. Interleukin-12 and -18 induce severe liver injury in mice recovered from peritonitis after sublethal endotoxin challenge. Surgery 2003, 134:92-100.